Novo Nordisk’s new ultra long-acting insulin degludec is associated with a higher heart risk than other diabetes treatments, although the size of the risk is uncertain, U.S. regulators said on Tuesday.
Read more
FDA staff highlight heart risk with Novo insulin
Posted in Glucose & Insulin